Danzinger Sabine, Filipits Martin
Institut für Krebsforschung, Universitätsklinik für Innere Medizin I, Medizinische Universität Wien, Wien, Osterreich.
Wien Med Wochenschr. 2007;157(21-22):554-61. doi: 10.1007/s10354-007-0483-x.
Tumor biology is increasingly important when choosing the optimal therapy for patients with non-small cell lung cancer (NSCLC). A number of potential biomarkers is under investigation in the hope that it will be possible to identify markers that assist in the selection of patients for specific therapies in the future. Patients with an elevated DNA repair capacity, indicated by an increased tumoral expression of excision repair cross complementation group-1 (ERCC1) or ribonucleotid reductase subunit M1 (RRM1) may benefit less from cisplatin-based and gemcitabine-based chemotherapy, respectively. Overexpression of the cell cycle regulator p27 affects response to various anticancer drugs and increased levels of class III beta-Tubulin are associated with taxane resistance. Promising results so far suggest that customized therapy for individual patients with the help of predictive biomarkers is possible and it is likely that this strategy will improve treatment of NSCLC in the future.
在为非小细胞肺癌（NSCLC）患者选择最佳治疗方案时，肿瘤生物学的重要性日益凸显。目前正在研究多种潜在的生物标志物，以期未来能够识别出有助于为特定治疗选择患者的标志物。DNA修复能力升高的患者，表现为切除修复交叉互补组-1（ERCC1）或核糖核苷酸还原酶亚基M1（RRM1）的肿瘤表达增加，可能分别从基于顺铂和基于吉西他滨的化疗中获益较少。细胞周期调节因子p27的过表达会影响对各种抗癌药物的反应，而III类β-微管蛋白水平的升高与紫杉烷耐药有关。迄今为止，有希望的结果表明，借助预测性生物标志物为个体患者定制治疗是可行的，而且这种策略很可能会在未来改善NSCLC的治疗。
